Biotech billionaire Kirk has a new, much bigger top line in mind

Randal "RJ" Kirk has made billions in the biotech business by focusing on the development of new and improved drugs. But now the CEO of synthetic biotech pioneer Intrexon ($XON) is thinking outside the healthcare box. "Biotech has a reverse footprint on the world. You should think beyond healthcare because if you want to know where the rapid growth in biotech is going to occur, it's going to be, in my opinion, highest in consumer, second highest in industrial, third highest in agriculture and then therapeutics," he told an audience in Florida. Story